Want to see CANF full AI Analyst Report?
Top Page
Can-Fite BioPharma
(CANF)
Select Model
Select Model
Rating:40Underperform
Price Target:
$1.50
▼(-54.82% Downside)
Action:Downgraded
Date:09/29/26
The score is primarily weighed down by very weak financial performance (minimal revenue, very large losses, and sustained negative free cash flow). Technicals also remain bearish with the price below key moving averages and a negative MACD, though near-oversold RSI/Stochastic slightly improves the outlook. Valuation provides limited support due to a negative P/E and no dividend yield data.
Positive Factors
Late-stage pipeline and regulatory support
Two lead candidates have reached Phase III development, while namodenoson benefits from Fast Track and orphan-drug designations. These regulatory pathways may streamline interactions and clarify potential approval routes, strengthening the pipeline’s strategic value if pivotal trials succeed.
Negative Factors
Minimal revenue and severe losses
The company has not yet established meaningful operating scale: revenue remains minimal while operating expenses produce losses vastly larger than sales. This weak earnings base limits internal funding capacity and makes future financial performance highly dependent on successful clinical development.
Read all positive and negative factors
Positive Factors
Negative Factors
Late-stage pipeline and regulatory support
Two lead candidates have reached Phase III development, while namodenoson benefits from Fast Track and orphan-drug designations. These regulatory pathways may streamline interactions and clarify potential approval routes, strengthening the pipeline’s strategic value if pivotal trials succeed.
Read all positive factors
Can-Fite BioPharma (CANF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.91M
Dividend YieldN/A
Average Volume (3M)50.34K
Price to Earnings (P/E)―
Beta (1Y)1.29
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.26
Shares Outstanding3,031,547
10 Day Avg. Volume31,707
30 Day Avg. Volume50,339
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)88.41
Price to Sales (P/S)1211.03
P/FCF Ratio-54.79
Enterprise Value/Market Cap-0.25
Enterprise Value/Revenue-3.66
Enterprise Value/Gross Profit-3.66
Enterprise Value/Ebitda0.15
Forecast
1Y Price Target
$8.00Price Target Upside140.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.68
Revenue Forecast (FY)N/A
Can-Fite BioPharma Business Overview & Revenue Model
Company Description
Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders...
How the Company Makes Money
Can-Fite BioPharma primarily seeks to generate value and future revenue by advancing its proprietary drug candidates through clinical development and then commercializing them either directly or via partners. As a clinical-stage company, its reven...
Can-Fite BioPharma Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
41
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 405.00K | 408.21K | 674.00K | 743.00K | 810.00K | 853.00K |
| Gross Profit | 405.00K | 384.02K | 674.00K | 743.00K | 810.00K | 853.00K |
| EBITDA | -9.73M | -10.00M | -8.12M | -8.18M | -10.08M | -12.83M |
| Net Income | -9.55M | -9.91M | -7.88M | -7.63M | -10.17M | -12.60M |
Balance Sheet | ||||||
| Total Assets | 8.05M | 9.51M | 9.12M | 9.99M | 9.28M | 20.25M |
| Cash, Cash Equivalents and Short-Term Investments | 7.04M | 8.54M | 7.89M | 8.92M | 7.98M | 19.14M |
| Total Debt | 49.00K | 71.00K | 104.00K | 40.00K | 62.00K | 124.00K |
| Total Liabilities | 3.20M | 3.92M | 3.68M | 3.75M | 4.81M | 5.87M |
| Stockholders Equity | 4.86M | 5.59M | 5.44M | 6.24M | 4.47M | 14.38M |
Cash Flow | ||||||
| Free Cash Flow | -9.51M | -9.02M | -7.64M | -8.44M | -10.81M | -9.87M |
| Operating Cash Flow | -9.51M | -9.02M | -7.64M | -8.44M | -10.80M | -9.86M |
| Investing Cash Flow | -4.00M | -2.02K | 1.50M | 498.00K | 9.50M | -14.51M |
| Financing Cash Flow | 10.04M | 9.72M | 6.71M | 9.14M | 0.00 | 20.46M |
Can-Fite BioPharma Technical Analysis
Negative
3.32
Price Trends
2.56
Negative
2.88
Negative
3.32
Negative
Market Momentum
-0.18
Negative
33.29
Neutral
12.82
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CANF, the sentiment is Negative. The current price of 3.32 is above the 20-day moving average (MA) of 2.07, above the 50-day MA of 2.56, and below the 200-day MA of 3.32, indicating a bearish trend. The MACD of -0.18 indicates Negative momentum. The RSI at 33.29 is Neutral, neither overbought nor oversold. The STOCH value of 12.82 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CANF.
Can-Fite BioPharma Risk Analysis
Can-Fite BioPharma disclosed 68 risk factors in its most recent earnings report. Can-Fite BioPharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
If a United States person is treated as owning at least 10% of our shares, such holder may be subject to adverse U.S. federal income tax consequences. Q4, 2023
Can-Fite BioPharma Peers Comparison
UnderperformOutperform
Sector (51)
CANF
Can-Fite BioPharma
1.89
-8.43
-81.69%
GNPX
Genprex
2.06
-305.94
-99.33%
BCDA
BioCardia
0.90
-0.57
-38.98%
PCSA
Processa Pharmaceuticals
1.73
-6.23
-78.27%
Can-Fite BioPharma Corporate Events
Can-Fite Case Report Shows Namodenoson Bridged Decompensated Cirrhosis Patient to Liver Transplant
Sep 9, 2026
On September 9, 2026, Can-Fite BioPharma reported a peer-reviewed case study in the Japanese Journal of Gastroenterology and Hepatology detailing Namodenoson treatment in a patient with advanced decompensated cirrhosis. The patient’s ascites...
Can-Fite BioPharma Reports Mid-2026 Results and Updates Drug Development Programs
Sep 8, 2026
On September 8, 2026, Can-Fite BioPharma filed a Form 6-K with the U.S. Securities and Exchange Commission reporting financial results for the six months ended June 30, 2026 and issuing unaudited interim condensed consolidated financial statements...
Can-Fite BioPharma Cuts Warrant Exercise Price to Secure $4 Million Inducement Financing
Sep 3, 2026
On September 2, 2026, Can-Fite BioPharma entered into an inducement offer with a holder of its March 5, 2026 warrants, cutting the exercise price from $5.00 to $2.50 per ADS for 1,591,738 ADSs in exchange for the holder’s immediate cash exer...
Can-Fite BioPharma Raises $4 Million Through Warrant Exercise to Fund Late-Stage Drug Pipeline
Sep 2, 2026
On September 2, 2026, Can-Fite BioPharma entered a definitive agreement for the immediate exercise of certain outstanding warrants, covering up to 1,591,738 ADSs originally issued in March 2026, at a reduced exercise price of $2.50 per ADS. The tr...
Can-Fite Flags Longer Survival in Phase III Liver Cancer Trial, Eyes Earlier Interim Analysis
Sep 2, 2026
On Sept. 2, 2026, Can-Fite BioPharma reported that blinded overall survival in its ongoing pivotal Phase III Namodenoson study in advanced hepatocellular carcinoma with Child-Pugh B7 cirrhosis is lasting longer than assumed in the original trial d...
Can-Fite Reports New Data Supporting Namodenoson Combo Strategy in Pancreatic Cancer
Aug 17, 2026
Can-Fite BioPharma reported on August 17, 2026 that new preclinical data show its oral A3 adenosine receptor agonist Namodenoson enhances the anti-cancer effect of gemcitabine chemotherapy in pancreatic cancer models. The combination increased lev...
Can-Fite BioPharma Advances Phase III Drug Candidates With Strengthened FDA and EMA Pathways
Aug 12, 2026
On August 12, 2026, Can-Fite BioPharma highlighted the advanced regulatory status of its two lead Phase III drug candidates, Piclidenoson and Namodenoson, under frameworks set by the U.S. Food and Drug Administration and the European Medicines Age...
Can-Fite BioPharma Starts First Piclidenoson Trial in Rare Lowe Syndrome
Aug 3, 2026
On August 3, 2026, Can-Fite BioPharma announced it has submitted a Phase 2 clinical study protocol to Bambino Gesù Children’s Hospital in Rome for the first clinical trial of its small-molecule drug Piclidenoson in patients with Lowe sy...
Can-Fite’s Namodenoson Pancreatic Cancer Data Accepted for ESMO 2026 Presentation
Jul 20, 2026
On July 20, 2026, Can-Fite BioPharma reported that positive Phase 2a data for its oral drug Namodenoson in advanced pancreatic ductal adenocarcinoma were accepted for poster presentation at the European Society for Medical Oncology Congress 2026. ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.